Clinical Trial Update: CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer [NA]

View source ↗

Summary

This completed trial evaluated CyberKnife-based radiotherapy as monotherapy or as a boost with SBRT for intermediate- to high-risk localized prostate cancer; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• CyberKnife

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Prostate Adenocarcinoma | NA | Status: COMPLETED | Results posted: 2024-10-01